Lactoferrin as an Adjuvant for Cellular Immunity

乳铁蛋白作为细胞免疫佐剂

• 批准号: 6552378
• 负责人: JEFFREY K ACTOR
• 金额: $ 10万
• 依托单位: PHARMAREVIEW CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-15 至 2004-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6552378
• 关键词: Bacillus Calmette Guerin vaccine; cellular immunity; immunologic substance development /preparation; immunomodulators; interleukin 12; interleukin 15; laboratory mouse; lactoferrin; tumor necrosis factor alpha; vaccine development; veterinary medicine

DESCRIPTION (provided by applicant): The overall goal of this project is to develop bovine and human Lactoferrins as an adjuvant to augment antibody and cell mediated immunity. We will specifically address the efficacy of Lactoferrin as an adjuvant to augment efficacy of BCG vaccination to subsequent challenge with virulent Mycobacterium tuberculosis. Improved nontoxic adjuvants, especially adjuvants capable of inducing (CM are needed for research use and for development of human and veterinary vaccines. The only adjuvant licensed for human use, alum, effectively enhances antibody formation, but is seldom effective for inducing CMI. Other adjuvants such as saponin and Complete Freund's that do induce CMI are much too toxic for use in humans and are being progressively restricted in animals. Lactoferrin is different from microbial derivative adjuvants, and from cytokines and growth factors; it is an effector molecule that directly participates in host defenses. Available evidence indicatesLactoferrin participates in the induction of immune responses, especially CMI. Preliminary studies demonstrate that lactoferrin as an adjuvant enhances delayed type hypersensitivity (DTH) in mice in a dose dependent fashion and has low toxicity. Furthermore, it induces IL-12, IL-15 and TNF-a production by macrophages thereby generating a local environment likely to push immune responses towards development of CMI.

描述（由申请人提供）：该项目的总体目标是开发牛和人乳铁蛋白作为增强抗体和细胞介导的免疫力的辅助。 我们将特别解决乳铁蛋白作为辅助性增强BCG疫苗接种疗效对随后对毒性分枝杆菌的挑战的疗效。 改进的无毒佐剂，尤其是能够诱导的佐剂（需要研究和开发人类和兽医疫苗需要CM）。唯一获得人使用的辅助剂有效地增强了抗体形成，很少有效地诱导CMI和诸如cmi的其他辅助剂。在动物中，乳酸蛋白与微生物衍生物佐剂不同，而细胞因子和生长因子是直接参与宿主防御的效应分子。此外，低毒性。它通过巨噬细胞诱导IL-12，IL-15和TNF-A产生，从而产生可能将免疫反应推向CMI的发展。

项目成果

Lactoferrin modulation of antigen-presenting-cell response to BCG infection.

乳铁蛋白调节抗原呈递细胞对 BCG 感染的反应。

• 发表时间: 2007
• 期刊: Postepy higieny i medycyny doswiadczalnej (Online)
• 作者: Wilk,KatarzynaM;Hwang,Shen-An;Actor,JeffreyK
• 通讯作者: Actor,JeffreyK